| Title |
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study
|
|---|---|
| Published in |
Investigational New Drugs, April 2013
|
| DOI | 10.1007/s10637-013-9962-7 |
| Pubmed ID | |
| Authors |
Tim Eisen, Yaroslav Shparyk, Nicholas Macleod, Robert Jones, Gudrun Wallenstein, Graham Temple, Yasser Khder, Claudia Dallinger, Matus Studeny, Arsene-Bienvenu Loembe, Igor Bondarenko |
| Abstract |
Some targeted anticancer agents are associated with serious ventricular tachyarrhythmias, which may be predicted by electrocardiographic evaluation of drug-related QT prolongation. We studied the effects of nintedanib (BIBF 1120; an oral, triple angiokinase inhibitor targeting vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor receptors) on the QT interval in patients with renal cell carcinoma (RCC) participating in an open-label phase II trial. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 3% |
| Spain | 1 | 3% |
| France | 1 | 3% |
| Unknown | 30 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 15% |
| Student > Ph. D. Student | 5 | 15% |
| Student > Doctoral Student | 4 | 12% |
| Other | 4 | 12% |
| Student > Postgraduate | 4 | 12% |
| Other | 8 | 24% |
| Unknown | 3 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 48% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Unspecified | 2 | 6% |
| Chemistry | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 5 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 April 2013.
All research outputs
#22,758,309
of 25,371,288 outputs
Outputs from Investigational New Drugs
#1,069
of 1,262 outputs
Outputs of similar age
#179,844
of 205,564 outputs
Outputs of similar age from Investigational New Drugs
#15
of 16 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,262 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 205,564 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.